Coherus Pulls A Rabbit Out Of The Hat With Inventive Pegfilgrastim Form
Firm Guiding For Q2 Launch, On-Body Injector Set To Follow Later In 2023
Coherus’ year-end financial results included a surprise – a newly approved formulation of pegfilgrastim.
You may also be interested in...
In the third part of this year’s Generics Bulletin Top 50, we look at how various increases and declines for companies at the bottom of our table have affected their positions in the ranking.
With Accord boasting a broad portfolio that encompasses generics, biosimilars, hybrid medicines and specialty products, Paul Tredwell – the firm’s executive vice-president for the Europe, Middle East and North Africa region – explains how this gives the company a unique position in the market.
Fresenius Kabi has delivered on long held ambitions to join the biosimilars party in the US, offering another pegfilgrastim subcutaneous injectable in a crowded market of biosimilar sponsors.